We acknowledge the assistance of Dr. Aleksandra Popadich and Dr. Mark Versnick for the collection of some preoperative blood samples, and we thank statistician Miss Jillian Patterson for statistical support.
MicroRNA-222 and MicroRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer
Version of Record online: 28 OCT 2013
© 2013 American Cancer Society
Volume 119, Issue 24, pages 4358–4365, 15 December 2013
How to Cite
Lee, J. C., Zhao, J. T., Clifton-Bligh, R. J., Gill, A., Gundara, J. S., Ip, J. C., Glover, A., Sywak, M. S., Delbridge, L. W., Robinson, B. G. and Sidhu, S. B. (2013), MicroRNA-222 and MicroRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer, 119: 4358–4365. doi: 10.1002/cncr.28254
- Issue online: 3 DEC 2013
- Version of Record online: 28 OCT 2013
- Manuscript Accepted: 17 MAY 2013
- Manuscript Revised: 13 MAY 2013
- Manuscript Received: 20 MAR 2013
- papillary thyroid cancer;
- tissue biomarkers;
- circulating biomarkers
Papillary thyroid cancer (PTC) persistence or recurrence and the need for long-term surveillance can cause significant inconvenience and morbidity in patients. Currently, recurrence risk stratification is accomplished by using clinicopathologic factors, and serum thyroglobulin is the only commercially available marker for persistent or recurrent disease. The objective of this study was to determine microRNA (miRNA) expression in PTC and determine whether 1 or more miRNAs could be measured in plasma as a biomarker for recurrence.
Patients with recurrent PTC (Rc-PTC) and those without recurrence (NR-PTC) were retrospectively recruited for a comparison of their tumor miRNA profiles. Patients with either newly diagnosed PTC or multinodular goiter who were undergoing total thyroidectomy were prospectively recruited for an analysis of preoperative and postoperative circulating miRNA levels. Healthy volunteers were recruited as the control group.
MicroRNA-222 and miR-146b were over-expressed 10.8-fold and 8.9-fold, respectively, in Rc-PTC tumors compared with NR-PTC tumors (P = .014 and P = .038, respectively). In plasma from preoperative PTC patients, levels of miR-222 and miR-146b were higher compared with the levels in plasma from healthy volunteers (P < .01 for both). Reductions of 2.7-fold and 5.1-fold were observed in the plasma levels of miR-222 and miR-146b, respectively, after total thyroidectomy (P = .03 for both).
This study demonstrated that tumor levels of miR-222 and miR-146b are associated with PTC recurrence and that miR-222 and miR-146b levels in the circulation correspond to the presence of PTC. The potential of these miRNAs as tumor biomarkers to improve patient stratification according to the risk of recurrence and as circulating biomarkers for PTC surveillance warrants further study. Cancer 2013;119:4358–4365. © 2013 American Cancer Society.